Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression signatures of dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib


ABSTRACT: Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measured with Agilent microarrays covering protein-coding genes and long (>200 nt) noncoding RNAs (lncRNAs). Sets of genes and lncRNAs significantly differentially expressed (>1.5 fold-change; q value ≤10%) were identified. Ingenuity Pathway Analysis pointed to a number of functions, canonical pathways and gene networks that were significantly enriched with differentially expressed genes. In addition to protein-coding genes, lncRNAs have been recently implicated in pathways leading to tumorigenesis. Our data point to new possible regulatory elements involved in dasatinib resistance in CML. This SuperSeries is composed of the SubSeries listed below. Refer to individual Series.

ORGANISM(S): Homo sapiens

SUBMITTER: Angela Fachel 

PROVIDER: E-GEOD-33290 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.

Silveira Rosana A RA   Fachel Angela A AA   Moreira Yuri B YB   De Souza Carmino A CA   Costa Fernando F FF   Verjovski-Almeida Sergio S   Pagnano Katia B B KB  

Hematology (Amsterdam, Netherlands) 20131125 1


Dasatinib has demonstrated efficacy in patients with chronic-phase chronic myeloid leukemia (CML) who had resistance or intolerance to imatinib. However, some patients also develop resistance or intolerance to dasatinib. To identify potential molecular pathways involved in primary resistance to dasatinib in CML, we analyzed gene expression profiles of mononuclear cells of 7 imatinib-resistant patients, collected before and after 1-year dasatinib treatment. Large-scale gene expression was measure  ...[more]

Similar Datasets

2013-07-31 | E-GEOD-33288 | biostudies-arrayexpress
2013-07-31 | E-GEOD-33224 | biostudies-arrayexpress
2014-05-30 | E-GEOD-57245 | biostudies-arrayexpress
2010-04-01 | E-GEOD-20130 | biostudies-arrayexpress
2011-05-09 | E-GEOD-29132 | biostudies-arrayexpress
2010-12-31 | E-GEOD-21719 | biostudies-arrayexpress
2010-10-08 | E-GEOD-20208 | biostudies-arrayexpress
2010-10-08 | E-GEOD-20207 | biostudies-arrayexpress
2010-10-08 | E-GEOD-20209 | biostudies-arrayexpress
2010-11-08 | E-GEOD-20210 | biostudies-arrayexpress